Education
About Us
Working with TipRanks
Follow Us
COSMO Pharmaceuticals N.V. (CH:COPN)
:COPN
COPN Stock Chart & Stats
CHF115.40
-CHF3.50(-5.38%)
At close: 4:00 PM EST
CHF115.40
-CHF3.50(-5.38%)
Day’s Range― - ―
52-Week RangeCHF41.60 - CHF129.40
Previous CloseN/A
Volume25.75K
Average Volume (3M)19.52K
Market Cap
CHF1.94B
Enterprise ValueCHF1.97B
Total Cash (Recent Filing)CHF126.63M
Total Debt (Recent Filing)CHF2.70M
Price to Earnings (P/E)35.4
Beta0.90
Next Earnings
Mar 09, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend Yield1.82%
Share Statistics
EPS (TTM)-0.11
Shares Outstanding17,543,522
10 Day Avg. Volume18,700
30 Day Avg. Volume19,520
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)2.22
Price to Sales (P/S)4.15
P/FCF Ratio7.07
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
CHF136.67Price Target Upside18.43% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthExtremely low leverage and a high equity ratio provide durable financial flexibility to fund R&D, commercial scale-up, or M&A without heavy borrowing. Strong ROE indicates efficient capital use, reducing refinancing risk and supporting long-term strategic optionality across business cycles.
Cash GenerationA very large improvement in free cash flow and FCF/net income ratios above 1.0 show the business can convert profits into cash sustainably. This strengthens self-funding capacity for pipeline investment, commercial expansion and reduces dependency on external capital over the medium term.
High ProfitabilityVery high gross and net margins suggest durable product economics likely driven by proprietary formulations and efficient manufacturing. Combined with strong recent revenue expansion, margins support sustained cash generation and reinvestment capacity, enhancing long-term competitive positioning.
Bears Say
Earnings Growth WeaknessNegative EPS growth is a structural warning sign that underlying earnings power has weakened recently. Persistent EPS declines can constrain reinvestment, limit dividend or buyback optionality, and indicate profitability volatility that could undermine long-term investor confidence if not reversed.
Revenue Volatility / Data InconsistencyConflicting growth metrics point to volatile or lumpy revenue recognition and potential inconsistency in top-line drivers. For a small, product-focused pharma, such volatility can impede forecasting, strain working capital planning, and make long-term revenue predictability and investment planning harder.
Dependence On Licensing & PartnershipsHeavy reliance on licensing, milestone payments and partner execution makes revenue lumpy and dependent on third-party commercialization capabilities. Partner delays or contract risks can materially affect cash flows and growth visibility, increasing structural execution risk over time.
COSMO Pharmaceuticals N.V. News
COPN FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest stock price was CHF41.60 and its highest was CHF129.40 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is CHF1.94B.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Mar 09, 2026 which is in 20 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Jul 23, 2025. The company reported -CHF0.115 earnings per share for the quarter, missing the consensus estimate of N/A by -CHF0.115.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. pays a Annually dividend of CHF1.918 which represents an annual dividend yield of 1.82%. See more information on COSMO Pharmaceuticals N.V. dividends here
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate is 0.18.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of -CHF0.115 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.711%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in CH:COPN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
COPN Stock 12 Month Forecast
Average Price Target
CHF136.67
▲(18.43% Upside)
Technical Analysis
Roche Holding AG
―
Basilea Pharmaceutica
―
Kuros Biosciences
―
medmix AG
―
Medartis Holding AG
―
Options Prices
Currently, No data available
---